Alcon News

    • Presbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1]
    • Dailies Total1® Multifocal contact lenses provide a seamless visual experience offering an alternative to bifocals or reading glasses.
    • They are designed to uniquely address end-of-day dryness and discomfort many contact lens wearers experience after age 40.[4]-[10]

    Basel, July 14, 2016 -Alcon, the global leader in eye care and a...

    • Innovative AcrySof® IQ PanOptix®  trifocal intraocular lens design to improve near to intermediate vision andincrease independence from glasses
    • More than three million cataract surgeries performed in Europe annually[1]

    Basel, Switzerland, June 16, 2015 - Alcon, the global leader in eye care and a division of Novartis, has received European CE Mark for its AcrySof® IQ PanOptix®trifocal intraocular lens (IOL) for patients undergoing cataract surgery who elect to address their near...

    •  Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire spectacle independence
    • US-based PowerVision, Inc. was formed to develop fluid-based accommodating intraocular lenses for cataract surgery patients
    • Fluid-based intraocular lens utilizes the eye's natural accommodative response to provide near and intermediate vision, in addition to distance vision...
    • Clareon®intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations
    • Congress program highlights Alcon's 70-year legacy of innovation including 100 million AcrySof®IOL implants
    • New analyses show efficacy and safety of CyPass® Micro-Stent in patients with glaucoma

    Basel, October 2, 2017 - Alcon, the global leader in eye care and a division of Novartis, will introduce Clareon®, the...

    • Nearly 65% of eyes treated with personalized topography-guided LASIK experienced 20/16 vision or better[1] in clinical study
    • Alcon is the first refractive laser manufacturer to receive FDA approval for a topography-guided LASIK procedure  
    • Alcon to further showcase new data in glaucoma treatments, cataract as well as refractive surgery procedures using Wavelight technology

    Basel, November 15, 2015 -Alcon, the global leader in eye care and a division of...

    • US Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US  
    • Expands Alcon's IOL portfolio for the  correction of near, intermediate and distance vision in patients undergoing cataract surgery,with increased independence from glasses  
    • More than three million cataract surgeries are performed each year in the US

    Basel, Switzerland, April 16, 2015 - Alcon, the global leader in eye care and a...

    • US Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States
    • Developed with efficacy data at 24 hours, post dose, to provide one-drop daily ocular itch relief associated with allergic conjunctivitis (eye allergies)
    • Up to 30% of the U.S. population is affected by seasonal allergy symptoms, with as many as 70 to 80% of these demonstrating ocular symptoms such as itching[1]

    Basel, February 2, 2015 - Alcon, the global...

    • Alcon is the global leader in the highly attractive and growing $23 billion eye care devices market
    • Market leading development capabilities and innovation investments
    • Clearly defined near and long-term strategy, focused on sales growth, operational excellence and free cash flow generation
    • 20,000+ employees dedicated to eye care, with a strong and experienced management team
    • Disciplined capital allocation strategy outlined

    New York, November 27, 2018 - Alcon, the eye care...